FDA Preventative Drugs Guidance Will Address Trial Design, Biomarkers
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency will host a workshop with DIA in the spring to explore new scientific strategies for developing preventative therapies, FDA's Gottlieb says.
You may also be interested in...
Deputy Commissioner Scott Gottlieb To Leave FDA Jan. 16
Gottlieb will return to the American Enterprise Institute to work on health policy issues with former FDA/CMS chief Mark McClellan.
Deputy Commissioner Scott Gottlieb To Leave FDA Jan. 16
Gottlieb will return to the American Enterprise Institute to work on health policy issues with former FDA/CMS chief Mark McClellan.
Diabetes Prevention Drugs Will Be Addressed In FDA Guidance
Metabolic syndrome may also be discussed in draft document expected to be out by year-end.